You are here: Home: BCU CME | 2005: Case 4: Select publications
 
     
 

SELECT PUBLICATIONS

Bross PF et al. Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 2003;9(12):4309-17. Abstract

Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest 2005;23(2):173-81. Abstract

Carlson RW. The history and mechanism of action of fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):5-8. Abstract

Franco S et al. Response to fulvestrant in heavily pretreated postmenopausal women: A single-center experience. Breast Cancer Res Treat 2004;88(2):103-8. Abstract

Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005;6(Suppl 1):23-9. Abstract

Howell A. The future of fulvestrant (“Faslodex”). Cancer Treat Rev 2005;31(Suppl 2):26-33. Abstract

Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004;22(9):1605-13. Abstract

Pippen J et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: A prospective combined survival analysis of two multicenter trials. Poster. San Antonio Breast Cancer Symposium 2003;Abstract 426.

Raina V. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women? Nat Clin Pract Oncol 2004;1(1):20-1. No abstract available

Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer 2003;98(2):229-38. Abstract

Vergote I, Abram P. Fulvestrant, a new treatment option for advanced breast cancer: Tolerability versus existing agents. Ann Oncol 2006;17(2):200-4. Abstract

 

 

 

 

  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office